- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/46 - Two or more oxygen, sulfur or nitrogen atoms
Patent holdings for IPC class C07D 239/46
Total number of patents in this class: 109
10-year publication summary
|
6
|
8
|
4
|
5
|
7
|
4
|
1
|
2
|
1
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2712 |
4 |
| Gilead Sciences, Inc. | 2222 |
4 |
| Vertex Pharmaceuticals Incorporated | 1582 |
3 |
| ADAMA Makhteshim Ltd. | 561 |
3 |
| Emory University | 1719 |
3 |
| Lek Pharmaceuticals d.d. | 181 |
3 |
| Memorial Sloan-Kettering Cancer Center | 2043 |
3 |
| Acea Therapeutics, Inc. | 31 |
3 |
| F. Hoffmann-La Roche AG | 7837 |
2 |
| The Regents of the University of California | 20745 |
2 |
| Boehringer Ingelheim International GmbH | 4493 |
2 |
| British Columbia Cancer Agency Branch | 182 |
2 |
| Eli Lilly and Company | 4101 |
2 |
| Flamma S.p.A. | 16 |
2 |
| Janssen Sciences Ireland UC | 158 |
2 |
| Purdue Pharmaceutical Products L.P. | 32 |
2 |
| Shionogi & Co., Ltd. | 880 |
2 |
| Socpra Sciences et Genie S.E.C. | 212 |
2 |
| Taisho Pharmaceutical Co., Ltd. | 852 |
2 |
| Versitech Limited | 309 |
2 |
| Other owners | 59 |